Questioning the 'neuroprotective' hypothesis: Does drug treatment prevent brain damage in early psychosis or schizophrenia?

British Journal of Psychiatry

Volumn 198, Issue 2, 2011, Pages 85-87

  Moncrieff, Joanna ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CLOZAPINE; HALOPERIDOL; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; PROTEIN BCL 2;

ALZHEIMER DISEASE; BRAIN DAMAGE; BRAIN SIZE; BRAIN TISSUE; BRAIN WEIGHT; DEGENERATIVE DISEASE; DISEASE DURATION; DRUG EFFECT; GLIOSIS; HIGH RISK POPULATION; HUMAN; HYPOTHESIS; MOOD DISORDER; NERVE CELL NECROSIS; NERVOUS SYSTEM DEVELOPMENT; NEUROIMAGING; NEUROPROTECTION; NEUROTROPISM; NONHUMAN; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; TEMPORAL LOBE; UPREGULATION;

ANTIPSYCHOTIC AGENTS; BRAIN DAMAGE, CHRONIC; HUMANS; NEUROPROTECTIVE AGENTS; PSYCHOTIC DISORDERS; SCHIZOPHRENIA;

EID: 79851505572     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.110.085795     Document Type: Review

References (23)

1. Information Centre for Health and Social Care. Prescription Cost Analysis 2008. NHS Information Centre, 2009.
2. Olfson M, Blanco C, Liu L, Moreno C, Laje G. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 2006; 63: 679-85. (Pubitemid 43848299)
3. Healy D. The latest mania: selling bipolar disorder. PLoS Med 2006; 3: e185.
4. Lieberman JA. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol Psychiatry 1999; 46: 729-39. (Pubitemid 29460898)
5. Lieberman JA, Tollefson GD, Charles C, Zipursky R, Sharma T, Kahn RS, et al. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry 2005; 62: 361-70. (Pubitemid 40471685)
6. Dorph-Petersen KA, Pierri JN, Perel JM, Sun Z, Sampson AR, Lewis DA. The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys. Neuropsychopharmacology 2005; 30: 1649-61. (Pubitemid 43086022)
7. Moncrieff J, Leo J. A systematic review of the effects of antipsychotic drugs on brain volume. Psychol Med 2010; 40: 1409-22.
8. Takahashi T, Wood SJ, Yung AR, Soulsby B, McGorry PD, Suzuki M, et al. Progressive gray matter reduction of the superior temporal gyrus during transition to psychosis. Arch Gen Psychiatry 2009; 66: 366-76.
9. Lawrie SM, Whalley HC, Abukmeil SS, Kestelman JN, Miller P, Best JJK, et al. Temporal lobe volume changes in people at high risk of schizophrenia with psychotic symptoms. Br J Psychiatry 2002; 181: 138-43. (Pubitemid 34864496)
10. Jarskog LF, Miyamoto S, Lieberman JA. Schizophrenia: new pathological insights and therapies. Annu Rev Med 2007; 58: 49-61. (Pubitemid 46706500)
11. Chen DC, Wang J, Wang B, Yang SC, Zhang CX, Zheng YL, et al. Decreased levels of serum brain-derived neurotrophic factor in drug-naive first-episode schizophrenia: relationship to clinical phenotypes. Psychopharmacology (Berl) 2009; 207: 375-80.
12. Jarskog LF, Glantz LA, Gilmore JH, Lieberman JA. Apoptotic mechanisms in the pathophysiology of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 846-58. (Pubitemid 40897803)
13. Morgan C, Abdul-Al R, Lappin JM, Jones P, Fearon P, Leese M, et al. Clinical and social determinants of duration of untreated psychosis in the ÆSOP first-episode psychosis study. Br J Psychiatry 2006; 189: 446-52. (Pubitemid 44683178)
14. Owens DC, Johnstone EC, Miller P, Macmillan JF, Crow TJ. Duration of untreated illness and outcome in schizophrenia: test of predictions in relation to relapse risk. Br J Psychiatry 2010; 196: 296-301.
15. Bosanac P, Patton GC, Castle DJ. Early intervention in psychotic disorders: faith before facts? Psychol Med 2010; 40: 353-8.
16. McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW, et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006; 163: 790-9. (Pubitemid 44464525)
17. Walker EF, Cornblatt BA, Addington J, Cadenhead KS, Cannon TD, McGlashan TH, et al. The relation of antipsychotic and antidepressant medication with baseline symptoms and symptom progression: a naturalistic study of the North American Prodrome Longitudinal Sample. Schizophr Res 2009; 115: 50-7.
18. Hunsberger J, Austin DR, Henter ID, Chen G. The neurotrophic and neuroprotective effects of psychotropic agents. Dialogues Clin Neurosci 2009; 11: 333-48.
19. Caldero J, Brunet N, Tarabal O, Piedrafita L, Hereu M, Ayala V, et al. Lithium prevents excitotoxic cell death of motoneurons in organotypic slice cultures of spinal cord. Neuroscience 2010; 165: 1353-69.
20. Bai O, Zhang H, Li XM. Antipsychotic drugs clozapine and olanzapine upregulate bcl-2 mRNA and protein in rat frontal cortex and hippocampus. Brain Res 2004; 1010: 81-6. (Pubitemid 38569855)
21. Jarskog LF, Glantz LA, Gilmore JH, Lieberman JA. Apoptotic mechanisms in the pathophysiology of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 846-58. (Pubitemid 40897803)
22. Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 2007; 64: 633-47. (Pubitemid 46878665)
23. Waddington JL, O'Callaghan E, Larkin C, Kinsella A. Cognitive dysfunction in schizophrenia: organic vulnerability factor or state marker for tardive dyskinesia? Brain Cogn 1993; 23: 56-70.